$15.63
+1.8%Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Chief Accounting Officer
Chief Administrative Officer
Chief Financial Officer
Compensation
$521,359
Chief Information Officer
Chief Operating Officer & President of Clinical Services
Compensation
$517,090
Chief Scientific Officer & President of Consulting Services
General Counsel & Corporate Secretary
Head of Investor Relations & Corporate Development
Interim Chief Executive Officer, Chairman of the Board & Lead Independent Director
Compensation
$110,000
President & Chief Commercial Officer
During the last 12 months, insiders have purchased $507K and sold $316K worth of FTRE shares, resulting in $191K of net buying activity.
0
0.00
6.6K
68.74K
-69K
-$69K
0
0.00
589
8.04K
-8K
-$8K
0
0.00
15.9K
160.78K
-161K
-$161K
72.4K
507.17K
9.8K
78.27K
+429K
+$429K
Neupert Peter M
Director
$407K
Russell Erin L
Director
$100K
Parks Robert
Officer: Chief Accounting Officer
$115K
Morais Mark A.
Officer: Chief Operating Officer
$96K
Mcconnell Jill G.
Officer: Chief Financial Officer
$88K
Hanson James S.
Officer: General Counsel
$17K
Moderately bullish with $191K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
FTRE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 28, 2024 | May 14, 2024 | 2024 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.